On the HCPLive Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.
April 22nd 2024
Announced on April 18, the approval is based on the VISIBLE 2 trial and comes less than 7 months after the approval of SC vedolizumab in ulcerative colitis.
Top 5 iPhone and iPad Apps for Patients with Irritable Bowel Syndrome
January 18th 2013It is important for patients with irritable bowel syndrome (IBS) to understand more about their condition and track their diet and bowel habits to help manage their symptoms. These apps for the iPhone and iPad provide useful information for patients that can help them learn more about the symptoms and management of IBS, track their medications and daily habits, and share this information with their health care providers.
Product News: Linzess for Irritable Bowel Syndrome with Constipation
January 17th 2013Linzess (linaclotide capsules) was approved in August 2012 by the FDA as a once-daily treatment for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC).
Assessing the Effectiveness of Psycho-Social Interventions in Reducing Symptom Severity in IBS
January 10th 2013Recent study results suggest that treatment that includes patient education, cognitive behavioral therapy, and other psycho-social modalities can help reduce symptom severity and improve quality of life in patients with irritable bowel syndrome (IBS).
IBD Patients May Suffer Increased Skin Cancer Risk
November 22nd 2011According to two recently published studies, the risk of skin cancer may be increased in individuals who suffer from inflammatory bowel disease (IBD); the risk is heightened by the use of immunosuppressant medications, which typically are used to treat IBD. At this time, there are no recommendations for skin cancer screenings in IBD individuals.
47th Annual Gastroenterology Update: Rationale for Combination Therapy in Inflammatory Bowel Disease
November 18th 2011Dr. Jean-Paul Achker said there is room for improvement of response rates with current treatment approaches. "There may be a limited window of time to maximize anti-TNFα therapy, as evidenced by the observed loss of response over time, the need to increase the dose of anti-TNFα therapy, and immunogenicity," he said.
47th Annual Gastroenterology Update: Biologic Therapies for Inflammatory Bowel Disease, Part 1
November 17th 2011Ahmed Kandiel, MD, MPH, kicked off the 47th Annual Gastroenterology Update with a thorough review of the current treatment landscape for moderate to severe inflammatory bowel disease, including the potential risks for side effects for each biologic agent.
Highlights from 47th Annual Gastroenterology Update at the Cleveland Clinic [Podcast]
November 17th 2011Bret Lashner, MD, MPH, FACG, shares his thoughts about the first day of the 47th Annual Gastroenterology Update at the Cleveland Clinic, including the recent developments with inflammatory bowel disease and hepatitis C therapy.